{"id":"cariprazine-flexible-dose","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"10-12","effect":"Headache"},{"rate":"8-10","effect":"Nausea"},{"rate":"7-9","effect":"Insomnia"},{"rate":"8-10","effect":"Restlessness"},{"rate":"5-8","effect":"Extrapyramidal symptoms"},{"rate":"5-7","effect":"Weight gain"},{"rate":"4-6","effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cariprazine selectively binds to dopamine D2 and D3 receptors with preferential affinity for D3, acting as a partial agonist to normalize abnormal dopaminergic signaling in the brain. It also has activity at serotonin 5-HT1A and 5-HT7 receptors. This multi-target mechanism helps reduce positive and negative symptoms in psychotic and mood disorders while potentially minimizing extrapyramidal side effects compared to typical antipsychotics.","oneSentence":"Cariprazine is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:02.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance treatment)"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT04777357","phase":"PHASE3","title":"A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.","status":"RECRUITING","sponsor":"AbbVie","startDate":"2021-04-28","conditions":"Depression, Bipolar I Disorder","enrollment":380},{"nctId":"NCT05913947","phase":"PHASE4","title":"Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2022-12-13","conditions":"Depression, Bipolar","enrollment":122},{"nctId":"NCT04578756","phase":"PHASE3","title":"Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-02-01","conditions":"Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)","enrollment":310},{"nctId":"NCT05439616","phase":"PHASE3","title":"Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Autism Spectrum Disorder","enrollment":161},{"nctId":"NCT04843423","phase":"PHASE4","title":"Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Dr. Martin A. Katzman","startDate":"2021-12-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":15},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT01104779","phase":"PHASE3","title":"Safety and Efficacy of Cariprazine in Schizophrenia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-04-27","conditions":"Schizophrenia","enrollment":446}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cariprazine Flexible Dose","genericName":"Cariprazine Flexible Dose","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cariprazine is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance treatment), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}